Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease

September 20, 2026 updated by: Fatima Yaman, Kutahya Health Sciences University

Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease

This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Kütahya, Turkey (Türkiye), 43020
        • Kutahya Health Sciences University
        • Contact:
        • Principal Investigator:
          • Fatima YAMAN, Assoc. Prof
        • Principal Investigator:
          • Meltem ÇOBAN, Dr.
        • Sub-Investigator:
          • Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
        • Sub-Investigator:
          • Mevlüt DEMİR, Assoc. Prof
        • Sub-Investigator:
          • Cansu OZBAYER, Prof. Dr.
        • Sub-Investigator:
          • Fatih KAR, Assoc. Prof.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Stable coronary artery disease
  • History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Referred and considered clinically eligible for a structured cardiac rehabilitation program
  • Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
  • Ability and willingness to participate in the study and complete the cardiac rehabilitation program

Exclusion Criteria:

  • Symptoms or signs of myocardial ischemia
  • Significant left ventricular outflow tract obstruction
  • Ventricular arrhythmia
  • Significant valvular heart disease
  • Uncontrolled hypertension
  • Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
  • Active malignancy
  • Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
  • Body mass index greater than 35 kg/m²
  • History of orthopedic surgery within the previous 6 months
  • Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
  • Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
  • Known psychiatric disorder
  • Presence of a permanent cardiac pacemaker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Personalized Cardiac Rehabilitation Group

Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.

Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in miRNA Expression Levels
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Peak Oxygen Uptake (VO₂max)
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Exercise Workload
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Six-Minute Walk Test Distance
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Resting Heart Rate
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Heart Rate
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Health-Related Quality of Life
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 30, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

September 20, 2026

First Submitted That Met QC Criteria

September 20, 2026

First Posted (Actual)

September 25, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 20, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KSBÜ-CR-miRNA-

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.